Sign In
Buy STOK
$28.86
-1.18 (-3.93%)
At Close: Jul 31, 2026
Stoke Therapeutics: Impressive Pipeline And Big Backers
11:27pm, Sunday, 15'th Jun 2025
Stoke Therapeutics is pioneering RNA-based therapies, with a lead candidate for Dravet Syndrome aiming for true disease modification, unlike current symptom-focused treatments. The company's pipeline
Stoke Therapeutics to Present at the Jefferies Global Healthcare Conference
07:30am, Thursday, 29'th May 2025
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h
Wall Street Analysts Think Stoke Therapeutics (STOK) Could Surge 132.4%: Read This Before Placing a Bet
11:01am, Friday, 16'th May 2025
The consensus price target hints at a 132.4% upside potential for Stoke Therapeutics (STOK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnin
Stoke Therapeutics, Inc. (STOK) Tops Q1 Earnings and Revenue Estimates
10:50am, Tuesday, 13'th May 2025
Stoke Therapeutics, Inc. (STOK) came out with quarterly earnings of $1.90 per share, beating the Zacks Consensus Estimate of a loss of $0.37 per share. This compares to loss of $0.57 per share a year
Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates
07:00am, Tuesday, 13'th May 2025
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h
Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
11:05am, Monday, 28'th Apr 2025
Stoke Therapeutics (STOK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stoke Therapeutics (STOK) Upgraded to Buy: What Does It Mean for the Stock?
01:00pm, Tuesday, 22'nd Apr 2025
Stoke Therapeutics (STOK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Stoke Therapeutics (STOK) Soars 12.0%: Is Further Upside Left in the Stock?
05:00am, Tuesday, 22'nd Apr 2025
Stoke Therapeutics (STOK) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength d
Stoke Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
04:30pm, Tuesday, 01'st Apr 2025
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h
Stoke Therapeutics Stock Slips as CEO Steps Down
12:56pm, Tuesday, 18'th Mar 2025
Shares of Stoke Therapeutics (STOK) slipped Tuesday as the drugmaker said its CEO Dr. Edward Kaye is stepping down from his role.
Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Tops Revenue Estimates
09:05am, Tuesday, 18'th Mar 2025
Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $0.60 per share a year ago.
Stoke Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
07:00am, Tuesday, 18'th Mar 2025
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h
Stoke Therapeutics Announces CEO Transition
06:58am, Tuesday, 18'th Mar 2025
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h
Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:00am, Monday, 17'th Mar 2025
Stoke Therapeutics (STOK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stoke Therapeutics to Present at Upcoming Investor Conferences in March
04:30pm, Wednesday, 26'th Feb 2025
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today
